Y-mAbs Therapeutics, Inc. (YMAB)

NASDAQ: YMAB · IEX Real-Time Price · USD
11.66
0.68 (6.19%)
May 27, 2022 4:00 PM EDT - Market closed
Market Cap509.75M
Revenue (ttm)40.00M
Net Income (ttm)-116.76M
Shares Out43.72M
EPS (ttm)-2.68
PE Ration/a
Forward PE119.05
Dividendn/a
Ex-Dividend Daten/a
Volume369,063
Open11.14
Previous Close10.98
Day's Range10.62 - 11.67
52-Week Range6.50 - 39.82
Beta1.47
AnalystsBuy
Price Target30.43 (+161.0%)
Earnings DateMay 9, 2022

About YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neurob...

IndustryBiotechnology
IPO DateSep 21, 2018
Employees148
Stock ExchangeNASDAQ
Ticker SymbolYMAB
Full Company Profile

Financial Performance

In 2021, YMAB's revenue was $34.90 million, an increase of 68.18% compared to the previous year's $20.75 million. Losses were -$55.28 million, -53.68% less than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is 30.43, which is an increase of 160.98% from the latest price.

Price Target
$30.43
(160.98% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) --  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...

1 day ago - GlobeNewsWire

YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 9.86% and 0.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments

NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializat...

2 weeks ago - GlobeNewsWire

Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022

NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter March 31, 2022 o...

3 weeks ago - GlobeNewsWire

Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline

YmAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago - Zacks Investment Research

Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...

1 month ago - GlobeNewsWire

Y-mAbs Announces Presentation of SADA Technology at AACR

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...

1 month ago - GlobeNewsWire

Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA

NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...

1 month ago - GlobeNewsWire

YmAbs Therapeutics, Inc. (YMAB) Soars 11.3%: Is Further Upside Left in the Stock?

YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...

2 months ago - Zacks Investment Research

Moore Kuehn, PLLC Encourages Investors of Y-mAbs Therapeutics, Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - March 17, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Y-mAbs Therapeutics, I...

2 months ago - Newsfile Corp

YmAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Misses Revenue Estimates

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -19.72% and 7.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...

3 months ago - GlobeNewsWire

Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline

YmAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA

Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.

3 months ago - Zacks Investment Research

Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab

NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...

3 months ago - GlobeNewsWire

YmAbs Therapeutics, Inc. (YMAB) Soars 8.3%: Is Further Upside Left in the Stock?

YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...

3 months ago - Zacks Investment Research

UPDATE - Y-mAbs Announces Pipeline Update

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...

5 months ago - GlobeNewsWire

Y-mAbs Hosting Virtual Research and Development Day

NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...

5 months ago - GlobeNewsWire

YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Misses Revenue Estimates

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -10.00% and -15.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the ...

6 months ago - Zacks Investment Research

Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments

NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...

6 months ago - GlobeNewsWire

Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma CNS/LM Metastasis

NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...

6 months ago - GlobeNewsWire

Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021

NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended September...

6 months ago - GlobeNewsWire

Y-mAbs Announces Data to be Presented at SIOP 2021

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, a...

8 months ago - GlobeNewsWire

Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China

NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”), NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commerciali...

8 months ago - GlobeNewsWire

Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neurobla...

NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...

8 months ago - GlobeNewsWire